BioMarin Pharmaceuticals BMRN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| ALDURAZYME | $196.27M-5.9% | $208.51M+5.2% | $198.16M-8.0% | $215.48M+9.0% | $197.6M+7.5% | |
| BRINEURA | $193.14M+3.6% | $186.4M+0.9% | $184.73M+6.3% | $173.78M+2.0% | $170.4M+0.8% | |
| KUVAN | $98.27M-1.3% | $99.53M-4.8% | $104.52M-3.8% | $108.61M-1.4% | $110.13M-8.9% | |
| NAGLAZYME | $501.18M+3.3% | $485.4M+2.2% | $475.18M-2.0% | $485.06M-0.7% | $488.25M+1.8% | |
| PALYNZIQ | $429.6M-0.9% | $433.31M+6.1% | $408.4M+4.6% | $390.25M+4.7% | $372.61M+4.9% | |
| ROCTAVIAN | $27.77M-22.1% | $35.64M+6.6% | $33.44M-10.8% | $37.49M+4.9% | $35.73M+37.1% | |
| Royalty and other revenues | $49.12M-8.2% | $53.49M+7.1% | $49.93M+7.4% | $46.48M+5.8% | $43.95M-1.2% | |
| VIMIZIM | $813.91M+2.8% | $792.05M+1.9% | $777.62M+0.6% | $773.02M+5.1% | $735.61M-0.6% | |
| VOXZOGO | $933.05M+0.7% | $926.92M+7.5% | $862.03M+3.4% | $833.43M+4.7% | $795.96M+8.3% | |
| R&D by Product | ||||||
| Later-stage clinical programs | $330.22M+7.1% | $308.33M+6.7% | $288.86M+511% | $47.29M+12.9% | $41.87M-62.7% | |
| Marketed products | $231.25M+0.6% | $229.89M-0.6% | $231.35M-2.4% | $237.15M-7.0% | $254.96M-10.7% | |
| Research and early pipeline | $380.53M-0.8% | $383.71M+0.2% | $382.81M-2.8% | $394M-2.5% | $404.1M-6.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioMarin Pharmaceuticals break its business down?
- BioMarin Pharmaceuticals (BMRN) reports total revenues by product across 9 parts — ALDURAZYME, BRINEURA, KUVAN, NAGLAZYME and PALYNZIQ. Each is extracted from the segment footnotes and tracked over time.
- Where does BioMarin Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioMarin Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
